{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:15:51Z","timestamp":1791490551273,"version":"4.3.4"},"reference-count":46,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    E1210 is a first-in-class, broad-spectrum antifungal with a novel mechanism of action\u2014inhibition of fungal glycosylphosphatidylinositol biosynthesis. In this study, the efficacies of E1210 and reference antifungals were evaluated in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. Oral E1210 demonstrated dose-dependent efficacy in infections caused by\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida<\/jats:named-content>\n                    species,\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus<\/jats:named-content>\n                    spp., and\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Fusarium solani<\/jats:named-content>\n                    . In the treatment of oropharyngeal candidiasis, E1210 and fluconazole each caused a significantly greater reduction in the number of oral CFU than the control treatment (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). In the disseminated candidiasis model, mice treated with E1210, fluconazole, caspofungin, or liposomal amphotericin B showed significantly higher survival rates than the control mice (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). E1210 was also highly effective in treating disseminated candidiasis caused by azole-resistant\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida albicans<\/jats:named-content>\n                    or\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Candida tropicalis<\/jats:named-content>\n                    . A 24-h delay in treatment onset minimally affected the efficacy outcome of E1210 in the treatment of disseminated candidiasis. In the\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus flavus<\/jats:named-content>\n                    pulmonary aspergillosis model, mice treated with E1210, voriconazole, or caspofungin showed significantly higher survival rates than the control mice (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05). E1210 was also effective in the treatment of\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus fumigatus<\/jats:named-content>\n                    pulmonary aspergillosis. In contrast to many antifungals, E1210 was also effective against disseminated fusariosis caused by\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">F. solani<\/jats:named-content>\n                    . In conclusion, E1210 demonstrated consistent efficacy in murine models of oropharyngeal and disseminated candidiasis, pulmonary aspergillosis, and disseminated fusariosis. These data suggest that further studies to determine E1210's potential for the treatment of disseminated fungal infections are indicated.\n                  <\/jats:p>","DOI":"10.1128\/aac.00366-11","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T23:57:58Z","timestamp":1311638278000},"page":"4543-4551","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":149,"title":["Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis"],"prefix":"10.1128","volume":"55","author":[{"given":"Katsura","family":"Hata","sequence":"first","affiliation":[{"name":"Next Generation Systems CFU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Horii","sequence":"additional","affiliation":[{"name":"Next Generation Systems CFU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamiko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Next Generation Systems CFU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao-aki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Next Generation Systems CFU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Okubo","sequence":"additional","affiliation":[{"name":"Biopharmaceutical Assessments CFU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Sonoda","sequence":"additional","affiliation":[{"name":"Biopharmaceutical Assessments CFU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Oncology PCU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Next Generation Systems CFU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuji","family":"Shirotori","sequence":"additional","affiliation":[{"name":"Oncology PCU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Murai","sequence":"additional","affiliation":[{"name":"Oncology PCU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Oncology PCU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Matsukura","sequence":"additional","affiliation":[{"name":"Oncology PCU, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Abe","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science &amp; Technology CFU, Eisai Product Creation Systems, Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Eisai Product Creation Systems, Eisai Co., Ltd., Bunkyo-ku, Tokyo 112-8088, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Asada","sequence":"additional","affiliation":[{"name":"Eisai Product Creation Systems, Eisai Co., Ltd., Bunkyo-ku, Tokyo 112-8088, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/652768"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5525-5529.2003"},{"key":"e_1_3_2_6_2","volume-title":"Approved standard. CLSI document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_7_2","volume-title":"Approved standard. CLSI document M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.02.004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1544"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2339"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/592578"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2243"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2237"},{"key":"e_1_3_2_14_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother","author":"Hata K.","year":"2010","unstructured":"HataK. HoriiT. MiyazakiM. WatanabeN.. 2010. Efficacy of E1210, a new broad-spectrum antifungal, in murine models of oropharyngeal candidiasis, disseminated candidiasis, and pulmonary aspergillosis, abstr. F1-842. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_15_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-843","author":"Horii T.","year":"2010","unstructured":"HoriiT. OkuboM. MiyazakiM. HataK. WatanabeN.. 2010. In vivo pharmacodynamic correlates of success for E1210 treatment of disseminated candidiasis. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-843."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.5.648"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/423274"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.11.3195-3197.2001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_2_20_2","volume-title":"Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-850","author":"Law D.","year":"2009","unstructured":"LawD. DobbK. FothergillA. PayneL. J. BirchM.. 2009. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-850."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022139"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.62-68.2002"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.5.1782-1787.2006"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01159-07"},{"key":"e_1_3_2_26_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-840","author":"Miyazaki M.","year":"2010","unstructured":"MiyazakiM. HoriiT. HataK. WatanabeN.. 2010. In vitro antifungal activity of E1210: a novel antifungal with activity against clinically important yeasts and moulds. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-840."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00291-11"},{"key":"e_1_3_2_28_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-847","author":"Motyl M. R.","year":"2010","unstructured":"MotylM. R. . 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-847."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.06.005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00014-07"},{"key":"e_1_3_2_31_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-844","author":"Okubo M.","year":"2010","unstructured":"OkuboM. ToritsukaN. HoriiT. HataK. SonodaJ.. 2010. Preclinical pharmacokinetics and toxicology of E1210, a new broad-spectrum antifungal. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-844."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/651262"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/323900"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02117-09"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00535-08"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01812.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.5.832"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2003.tb03403.x"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1246\/cl.2010.1033"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03481.x"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301044200"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.159.3.679"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc061720"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_2_46_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-841","author":"Watanabe N.","year":"2010","unstructured":"WatanabeN. HoriiT. MiyazakiM. HataK.. 2010. E1210, a new broad-spectrum antifungal, inhibits glycosylphosphatidylinositol (GPI) biosynthesis and affects Candida albicans cell characteristics. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-841."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00366-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00366-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:55:07Z","timestamp":1645462507000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00366-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1128\/AAC.00366-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00366-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"2011-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}